Prostate cancer decisions — 2026

The Veteran's prostate cancer associated with herbicide exposure is granted effective February 20, 2023.,The Veteran's erectile dysfunction secondary to his service-connected prostate cancer is also granted effective February 20, 2023. SMC based on loss of use of a creative organ due to erectile dysfunction and SMC based on housebound status are both granted effective February 20, 2023.,The Veteran's eligibility for Dependents Educational Assistance (DEA) is granted effective February 20, 2023.

The Veteran's prostate cancer is presumed to be related to his in-service herbicide agent exposure, and service connection for prostate cancer is granted.

The Board has determined that the Veteran's death was not caused by any service-connected disability, and thus denied his claim for service connection for cause of death.

The Board denied the Veteran's claim for service connection for prostate cancer and prostate cancer residuals, finding insufficient evidence of herbicide exposure during service to establish a direct link.

The Veteran's urinary sphincter dysfunction is restored to a 40 percent rating effective February 1, 2025. A higher rating for the condition beginning July 12, 2023, is denied.

The Veteran's residuals of prostate cancer are rated at 60 percent, and he is granted a TDIU due to his service-connected disabilities preventing him from securing or following a substantially gainful occupation.

The Veteran's appeal for a TDIU based on his service-connected prostate cancer residuals with urinary dysfunction is dismissed as moot because he is already receiving a 100% disability rating.

The Board has restored service connection for hypertension, prostate cancer with urinary incontinence, erectile dysfunction, and obstructive sleep apnea as the November 2025 AOJ decision was void ab initio due to failure to comply with proper procedural steps.

The Board has remanded the claims of entitlement to service connection for prostate cancer, basal cell carcinoma on the forehead, and melanoma on the right ear due to a duty to assist error. The Veteran's exposure to herbicide agents during his service in Korea is not presumed, but he may still establish direct service connection.

The Veteran's claims for service connection for prostate cancer and allergic rhinitis are being remanded due to duty-to-assist errors. The Board is unable to consider evidence submitted after the AOJ decision on appeal, but any such evidence will be considered by the AOJ in the readjudication.

The reduction in the Veteran's disability evaluation for prostate cancer was improper and the 40 percent rating is restored, effective November 19, 2024.

Service connection for chronic sinusitis is granted due to presumed exposure to burn pits and other toxins during service in the Southwest Asia theater of operations.,Service connection for bronchitis is denied as there is no evidence that it began during service or is related to an in-service injury or disease.

The appeal concerning the earlier effective date for prostate cancer service connection is dismissed due to the Veteran's death.

The Veteran's service-connected conditions, including psychiatric disability and various scars, have resulted in unemployability. The Board has granted a TDIU based on the combined rating of 80 percent.

The Board denied service connection for prostate cancer and rash, finding that the Veteran did not serve at Camp Lejeune where exposure to contaminated water is presumed. The conditions are deemed unrelated to service.

The Veteran's claim for service connection for erectile dysfunction is granted. The claims for increased ratings for prostate cancer and voiding dysfunction, as well as the TDIU and renal dysfunction claims are remanded due to pre-decisional duty to assist error.

The Veteran's application for a compensable rating for his service-connected prostate cancer was denied in April 2025. The Board has now ordered the case to be remanded due to duty-to-assist errors.

The Board denied service connection for prostate cancer and associated residuals (claimed as testicular cancer) and thyroid cancer, finding that the evidence did not support a link to military service or exposure.

The Board has remanded the case due to a lack of a VA examination and medical opinion regarding the relationship between the Veteran's prostate cancer and his military service, specifically his exposure at Camp Lejeune. The Veteran contends that his prostate cancer is related to TCE exposure during his time at Camp Lejeune.

The Veteran's prostate cancer residuals resulted in daytime voiding interval between 1 and 2 hours, warranting a 20 percent rating from September 12, 2024.